Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

Eligibility Criteria

• 1. Active proliferative LN Class III or IV either with or without the presence of Class V according to the 2003 ISN/RPS classification
• 2. Renal biopsy obtained within 6 months prior to signing the ICF or during Screening Period.
• 3. Urine protein to creatinine ratio \> 1 mg/mg (113.17 mg/mmol)
• 4. eGFR ≥ 35 mL/min/1.73 m2 (as calculated by the Chronic Kidney Disease Epidemiology Collaboration formula).
• 5. Fulfills updated 2019 EULAR/ACR SLE classification criteria.
• 6. No signs of symptoms of active TB prior to or during screening or no treatment for latent TB
• 1. A diagnosis of pure Class V LN based on the renal biopsy obtained within 6 months prior to signing the ICF or during Screening.
• 2. Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection, or a positive result for HIV confirmed by the central lab at Screening - an HIV test must be performed during Screening, and the result should be available prior to Week 0 (Day 1).
• 3. Evidence of hepatitis C or active hepatitis B.
• 4. Any history of cancer except sucessfully cured skin squamos or basal skin carcinoma and cervical cancer in situ.
• 5. Receipt of the following for the current LN flare (ie, since the qualifying renal biopsy): IV cyclophosphamide \> 2 pulses of high-dose (≥ 0.5 g/m2) or \> 4 doses of low dose (500 mg every 2 weeks) or Average MMF \> 2.5 g/day (or \> 1800 mg/day of enteric coated mycophenolate sodium) for more than 8 weeks or Tacrolimus \> 4 mg/day for more than 8 weeks; Cyclosporine for more than 8 weeks or during last 8 weeks prior to signing the ICF; Voclosporin for more than 8 weeks or during last 8 weeks prior to signing the ICF; Belimumab for more than 12 weeks or during last 12 weeks prior the ICF.
• 6. Previous receipt of \>◦2 investigation treatments (other than anifrolumab) for LN or SLE since time of diagnosis and through the ICF.
• 7. Known intolerance to ≤ 1.0 g/day of MMF.
• 8. Any history of severe COVID-19 infection.